Bumper Number Of 'Oral Explanations' Due At CHMP Meeting

An unusually large number of companies are due to appear this week before the European Medicines Agency’s key advisory panel, the CHMP, to answer questions about initial marketing authorization applications or indication extension requests. The CHMP has questions regarding nine different products.

Notes
The CHMP has the questions. Do companies have the answers? • Source: Shutterstock

The sponsors of seven products in the later stages of the EU evaluation process are due to appear this week before the European Medicine Agency’s key advisory panel, the CHMP, to address outstanding concerns the panel has regarding their applications. Additionally, two companies seeking to extend the indications of already marketed products will appear before the committee to address concerns relating to their requests.

The CHMP may to decide issue an opinion on whether two of the seven initial marketing authorization applications (MAAs) –...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography